Upstream Bio, Inc. (UPB)
$3.55-14.87%Close
SELLCRISIS · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $193M
- Short % float
- 22.48%
- Days to cover
- 7.7
- SI change
- +0.5%
- 1W
- -22.66%
- 1M
- -38.90%
- vs SPY 1W
- -22.52%
- vs SPY 1M
- -41.40%
Industry peers
FMP comparable companies · ranked by market cap
- SYRESELLSpyre Therapeutics, Inc.$7.4BCRISISQ 9$85.69-6.34%
- TERNTerns Pharmaceuticals, Inc.$6.1B$52.95
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 2$17.88-3.45%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BCRISISQ 7$28.14-2.29%
- PHVSSELLPharvaris N.V.$2.2BCRISISQ 15$31.10-2.82%
- NVAXBUYNovavax, Inc.$2.1BBULLQ 10$12.75+1.26%
- NTLABUYIntellia Therapeutics, Inc.$1.8BRECOVERYQ 3$13.07-5.33%
- ZBIOSELLZenas BioPharma, Inc.$1.7BCRISISQ 12$27.26-4.70%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.99-15.71%
- WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-4.27%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on UPB?
- LOPJLB’s latest quantitative signal on Upstream Bio, Inc. (UPB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is UPB in?
- Upstream Bio, Inc. (UPB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Upstream Bio, Inc. (UPB) do?
- Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively develo…